

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP
CONVEYING PARTY DATA	
Name	Execution Date
Amylin Pharmaceuticals, LLC	09/19/2012
RECEIVING PARTY DATA	
Name:	AstraZeneca Pharmaceuticals LP
Street Address:	1800 Concord Pike
City:	Wilmington
State/Country:	DELAWARE
Postal Code:	19803
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12640352
CORRESPONDENCE DATA	
Fax Number:	2024676910
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(202) 467-6900
Email:	ipdocketing@wcsr.com
Correspondent Name:	Womble Carlyle Sandridge & Rice LLP
Address Line 1:	1200 Nineteenth Street
Address Line 2:	Suite 500
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20036
ATTORNEY DOCKET NUMBER:	A68761 1620US.C1
NAME OF SUBMITTER:	Alireza Behrooz
Total Attachments: 4 source=AmylinAstraZenecaAssignment#page1.tif source=AmylinAstraZenecaAssignment#page2.tif source=AmylinAstraZenecaAssignment#page3.tif source=AmylinAstraZenecaAssignment#page4.tif	

CH \$40.00 12640352

ASSIGNMENTS OF PATENTS AND PATENT APPLICATIONS

This Assignment of Patents and Patent Applications, effective as of August 8, 2012, is by and between Amylin Pharmaceuticals, LLC (hereinafter referred to as "Assignor"), a Delaware limited liability company having offices at 9360 Towne Centre Drive, San Diego, California, USA, as successor in interest to Amylin Pharmaceuticals, Inc., and AstraZeneca Pharmaceuticals LP (hereinafter referred to as "Assignee"), a Delaware limited partnership having offices at 1800 Concord Pike, Wilmington, Delaware, USA.

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby assign to Assignee an equal and undivided one-half of its entire right, title and interest in and to each of the patents and patent applications listed in the Exhibit A attached hereto, including any continuations, continuations-in-part, divisional, reissues, reexaminations and renewals thereof, corresponding supplementary protection certificates and the like and extensions thereof (hereinafter referred to as "Assigned Patents"). This assignment includes the grant by the Assignor to the Assignee of the right to claim priority for the Assigned Patents under the International Convention for the Protection of Industrial Property and under any similar international arrangement to which the United States of America is or hereafter becomes a signatory.

IN WITNESS WHEREOF, the Assignor has caused this assignment to be executed this 19th day of September, 2012 at Princeton, New Jersey.

ASSIGNOR:


Amylin Pharmaceuticals, LLC

By: 

Henry Hadad
Vice President and Deputy General Counsel IP,
Bristol-Myers Squibb Company,
parent of Amylin Pharmaceuticals, LLC

STATE OF New Jersey)
)
COUNTY OF Berlin)

On the 19th day of September, 2012 before me personally came Henry H. Hadad, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as Vice President and Deputy General Counsel of IP at Bristol-Myers Squibb Company, the parent to Amylin Pharmaceuticals, LLC, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).



ANNE BARTHOLOMEW

Notary Public of New Jersey


My Commission Expires March 23, 2016

Page 1 of 64

IN WITNESS WHEREOF, the Assignee acknowledges and accepts this assignment this 18th day of September, at Wilmington, Delaware.

ASSIGNEE:

AstraZeneca Pharmaceuticals LP

By: 


Stephen F. Mohr
US General Counsel and
Regional Legal Director, Americas
AstraZeneca Pharmaceuticals LP,

STATE OF)
) ss
COUNTY OF)

On the 18th day of September 2012, before me personally came Stephen F. Mohr, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as US General Counsel and Regional Legal Director, Americas of AstraZeneca Pharmaceuticals LP, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

Notary Public





**Exhibit A to Patent Assignment Effective August 8, 2012
Between Amylin Pharmaceuticals, LLC and AstraZeneca Pharmaceuticals LP**

Docket No.	Country	Title	App. No.	App. Date	Patent No.	Grant Date
0101PCT	PCT	Treatment of Pancreatitis with Amylin	PCT/US2003/30224PC	9/24/2003		
0101US-PRO	United States	Treatment of Pancreatitis with Amylin	60/413419	9/24/2002		
0101US-PRO2	United States	Treatment of Pancreatitis with Amylin	60/419440	10/18/2002		
0101US-UTL	United States	Treatment of Pancreatitis with Amylin	10/671304	9/24/2003	8168233	5/1/2012
0102AU	Australia	Use of Amylin Agonists to Modulate Triglycerides	2003235742	1/8/2003	2003235742	11/21/2008
0102CA	Canada	Use of Amylin Agonists to Modulate Triglycerides	2475173	1/8/2003		
0102DE	Germany	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	60324387.8-08	10/29/2008
0102EP	Europe	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	1474164	10/29/2008
0102ES	Spain	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	2316757	10/29/2008
0102FR	France	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	1474164	10/29/2008
0102GB	Great Britain	Use of Amylin Agonists to Modulate Triglycerides	3729360.2	1/8/2003	1474164	10/29/2008
0102IT	Italy	Use of Amylin Agonists to Modulate Triglycerides	EP 1474164	1/8/2003	33771 BE/2008	10/29/2008
0102NZ	New Zealand	Use of Amylin Agonists to Modulate Triglycerides	534557	1/8/2003	534557	2/8/2008
0102PCT	PCT	Use of Amylin Agonists to Modulate Triglycerides	PCT/US2003/00369	1/8/2003		
0102US-PRO	United States	Use of Amylin Agonists to Modulate Triglycerides	60/347128	1/8/2002		
0102US-UTL	United States	Use of Amylin Agonists to Modulate Triglycerides	10/337979	1/8/2003		
0103AU	Australia	Formulations for Amylin Agonist Peptides	2003238862	5/30/2003	2003238862	11/13/2008
0103NZ	New Zealand	Formulations for Amylin Agonist Peptides	536813	5/30/2003	536813	9/13/2007
0103PCT	PCT	Formulations for Amylin Agonist Peptides	PCT/US2003/17226	5/30/2003		
0103US-CIP1	United States	Formulations for Amylin Agonist Peptides	10/159779	5/31/2002	7312196	12/25/2007

0406PCT	PCT	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	PCT/US2005/004351	2/11/2005		
0406PCT2	PCT	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	PCT/US2005/045471	12/12/2005		
0406PH2-D1-LL	Philippines	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	1-2010-520572	12/12/2005		
0406PH2-LL	Philippines	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	1-2007-501212	12/12/2005	1-2007-501212	4/18/2011
0406RU2-LL	Russia	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	2007126653	12/12/2005	2427586	8/27/2011
0406SG2-D2-LL	Singapore	Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same	201200776-1	12/12/2005		
0406US-CIP	United States	Pancreatic Polypeptide Family Motifs and Polypeptides and Methods Comprising the Same	11/301744	12/12/2005	7723471	5/25/2010
0406US-CON1-LL	United States	Pancreatic Polypeptide Family Motifs and Polypeptides and Methods Comprising the Same	12/640352	12/17/2009		
0406US-PRO	United States	PYY Analog Polypeptide Compositions and Methods	60/543406	2/11/2004		
0406US-UTL	United States	Pancreatic Polypeptide Family Motifs and Polypeptides Comprising the Same	11/055098	2/11/2005		
0406WO	PCT					
0410US-PRO1	United States	Pharmaceutical Compositions Comprising Microcrystalline Suspensions of Y Receptor Agonists for Extended Delivery of Such, and Methods and Uses for the Same	61/363200	7/9/2010		
0410WO1	PCT	Microcrystalline Y Receptor Agonists	PCT/US2011/043420	7/8/2011		
0501EP1-LL	Europe	Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins	4754133.9	5/28/2004		
0501PCT	PCT	Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins	PCT/US2004/017456	5/28/2004		
0501PCT2	PCT	Improved Transmucosal Delivery of Peptides and Proteins	PCT/US2005/001440	1/12/2005		
0501US-PRO	United States	Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins	60/474233	5/30/2003		
0501US-UTL1-LL	United States	Methods and Compositions for Enhanced Transmucosal Delivery	10/559595	5/28/2004	8008255	8/30/2011

Page 27 of 64